Drs. Stephen Liu and Benjamin Weinberg of Lombardi Comprehensive Cancer Center elaborate on the prevalence of NRG1 gene fusions in pancreatic ductal adenocarcinoma (PDAC), strategies they recommend for effectively identifying these fusions in clinical practice, and observed response rates and survival outcomes for PDAC patients treated with zenocutuzumab in a recent NEJM publication.
Advertisement
Latest News
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Maen Abdelrahim reflects on the multidisciplinary collaboration required to make transplant oncology a clinical reality.
Palliative EBRT can reduce physician-evaluated and patient-reported dysphagia symptoms in patients with incurable disease.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Dr. Ashwin Somasundaram discusses the results of a recent phase 2 study of ipilimumab, nivolumab, and panitumumab for mCRC.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
CheckMate-8HW remains in progress to determine secondary end points such as overall survival.
Advertisement
Advertisement
Editorial Advisory Board
Christopher Lieu, MDEditor | Co-Director of Gastrointestinal Medical Oncology at University of Colorado Medicine
Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center
Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles
Roundtable Discussions
Conference Coverage
GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.
Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting
The latest news and research updates in GI cancer treatment from the ESMO Congress 2024
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.